Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NR82: Variant p.Pro369Arg

Potassium voltage-gated channel subfamily KQT member 5
Gene: KCNQ5
Feedback?
Variant information Variant position: help 369 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Proline (P) to Arginine (R) at position 369 (P369R, p.Pro369Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (P) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In MRD46; no effect on protein abundance; no effect on potassium ion transmembrane transport; increased voltage-gated potassium channel activity; changed gating properties resulting in a gain of function. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 369 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 932 The length of the canonical sequence.
Location on the sequence: help GFALKVQEQHRQKHFEKRRN P AANLIQCVWRSYAADEKSVS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         GFALKVQEQHRQKHFEKRRNPAANLIQCVWRSYAADEKSVS

Mouse                         GFALKVQEQHRQKHFEKRRNPAANLIQCVWRSYAADEKSVS

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 932 Potassium voltage-gated channel subfamily KQT member 5
Topological domain 347 – 932 Cytoplasmic
Helix 367 – 382



Literature citations
Loss-of-function and gain-of-function mutations in KCNQ5 cause intellectual disability or epileptic encephalopathy.
Lehman A.; Thouta S.; Mancini G.M.S.; Naidu S.; van Slegtenhorst M.; McWalter K.; Person R.; Mwenifumbo J.; Salvarinova R.; Guella I.; McKenzie M.B.; Datta A.; Connolly M.B.; Kalkhoran S.M.; Poburko D.; Friedman J.M.; Farrer M.J.; Demos M.; Desai S.; Claydon T.;
Am. J. Hum. Genet. 101:65-74(2017)
Cited for: INVOLVEMENT IN MRD46; VARIANTS MRD46 GLY-145; ILE-341; ARG-369 AND ILE-429; CHARACTERIZATION OF VARIANTS MRD46 GLY-145; ILE-341; ARG-369 AND ILE-429; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.